Radiopharm Theranostics Limited Sponsored ADR (RADX) AI Stock Analysis

• Market Cap: $49.93M
• Dividend Yield: N/A
• Average Volume (3M): 43.36K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.19
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -2.11
• Shares Outstanding: 11,814,054
• 10 Day Avg. Volume: 44,863
• 30 Day Avg. Volume: 43,361
• PEG Ratio: 0.01
• Price to Book (P/B): 1.09
• Price to Sales (P/S): 13.46
• P/FCF Ratio: -1.33
• Enterprise Value/Market Cap: 0.40
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $30.00
• Price Target Upside: 525.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -3.21
• Revenue Forecast (FY): $581.03K

• Rating: 47 Neutral
• Price Target: $5.00 ▲(4.17% Upside)
• Action: N/A Date: 01/04/26
• Date: Action: N/A 01/04/26

The score is held down primarily by sustained losses and persistent cash burn (negative operating and free cash flow), despite some revenue momentum. Technical signals are largely neutral with only mild positives, offering limited support. Valuation is difficult to assess due to negative earnings, and no dividend data is available.

Radiopharm Theranostics Limited Sponsored ADR Business Overview & Revenue Model

Company Description

Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting avß6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, an avß6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors. It has strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.

How the Company Makes Money

null

Radiopharm Theranostics Limited Sponsored ADR Financial Statement Overview

Summary

Early-stage profile with improving revenue off a small base, but profitability is very weak with large operating losses and deeply negative margins. Cash flow remains consistently negative with worsening free cash flow in FY2025, indicating ongoing cash burn and likely continued external funding needs. The main offset is a conservative balance sheet with zero debt, reducing near-term financial risk.

Income Statement

Revenue is growing off a very small base, with FY2025 revenue up meaningfully versus prior years. However, profitability remains very weak: gross profit is minimal in FY2025 and operating losses are very large relative to sales, resulting in deeply negative net margins across all periods. Overall, the income statement reflects an early-stage biotech profile with improving topline traction but no visible path to near-term earnings.

Balance Sheet

The balance sheet is a relative strength: total debt is reported at zero across all years, which reduces financial risk and refinancing pressure. Equity remains sizable, but it has been volatile and return on equity is consistently and materially negative, reflecting ongoing losses that erode shareholder value. In short, leverage is conservative, but the company’s capital base is being consumed by persistent unprofitability.

Cash Flow

Cash generation is weak, with negative operating cash flow and negative free cash flow in every year provided, indicating continued cash burn to fund operations. Free cash flow deterioration in FY2025 versus FY2024 adds pressure, and cash flow does not yet show signs of self-funding scalability. While cash burn is typical for development-stage biotech, the current run-rate implies ongoing dependence on external capital over time.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2022
Income Statement
Total Revenue	3.63M	299.23K	292.36K	8.83K
Gross Profit	39.28K	299.23K	292.36K	8.83K
EBITDA	-38.17M	-44.08M	-31.19M	-17.96M
Net Income	-38.34M	-47.95M	-34.61M	-30.34M
Balance Sheet
Total Assets	86.48M	72.04M	74.95M	83.38M
Cash, Cash Equivalents and Short-Term Investments	29.12M	18.58M	11.70M	26.98M
Total Debt	0.00	0.00	0.00	0.00
Total Liabilities	43.61M	44.68M	29.37M	20.42M
Stockholders Equity	44.79M	28.12M	44.38M	62.96M
Cash Flow
Free Cash Flow	-36.65M	-22.98M	-24.73M	-38.25M
Operating Cash Flow	-36.65M	-22.98M	-23.20M	-9.92M
Investing Cash Flow	1.77M	-320.00K	-1.53M	-28.37M
Financing Cash Flow	45.43M	30.20M	9.22M	65.11M

Radiopharm Theranostics Limited Sponsored ADR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ACRV	49 Neutral	$64.32M	-1.19	-53.71%	―	―	21.17%
RADX	47 Neutral	$49.93M	-1.28	―	―	―	―
BRNS	46 Neutral	$25.73M	-0.43	-70.57%	―	-100.00%	-26.30%
SER	45 Neutral	$27.40M	-3.02	―	―	―	―
CELU	44 Neutral	$35.18M	-0.59	763.31%	―	-15.81%	-113.06%

Radiopharm Theranostics Limited Sponsored ADR Corporate Events

Radiopharm Theranostics Doses First Patient in Phase 1/2a Trial of 177Lu-BetaBart

On 24 February 2026 Radiopharm Theranostics announced it had dosed the first patient in a First-In-Human Phase 1/2a clinical trial of 177Lu-BetaBart (RV-01), a radiotherapeutic developed through Radiopharm Ventures, its joint venture with The University of Texas MD Anderson Cancer Center. The agent is a Lu-177–tagged monoclonal antibody targeting the 4Ig isoform of B7-H3, an immune checkpoint molecule overexpressed in several tumor types, and preclinical studies have shown tumor shrinkage and prolonged survival in animal models.

The Phase 1/2a study, which follows prior FDA IND clearance in July 2025, is designed as a dose-escalation and expansion trial to assess safety, biodistribution, pharmacokinetics, radiation dosimetry and preliminary anti-tumor activity, and to establish a recommended dose for future studies. Radiopharm plans to enroll 61 patients with various advanced refractory solid tumors, including prostate, colorectal, lung, head and neck, ovarian and triple-negative breast cancers, marking a significant milestone as the first radiotherapeutic from the joint venture to enter the clinic and potentially broadening the company’s footprint in targeted radiopharmaceutical oncology.

The most recent analyst rating on (RADX) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited Sponsored ADR stock, see the RADX Stock Forecast page.

Radiopharm Theranostics Lifts Stake in MD Anderson Joint Venture to 87.5% as Lead B7H3 Drug Enters Clinic

On 12 January 2026, Radiopharm Theranostics announced it had increased its ownership stake in Radiopharm Ventures, LLC, its radiopharmaceutical joint venture with The University of Texas MD Anderson Cancer Center, from 75% to 87.5%, signalling heightened confidence in the venture’s oncology pipeline. The move follows U.S. FDA IND clearance in July 2025 for Betabart (RV01), a B7H3‑targeting monoclonal antibody radiolabelled with lutetium-177, which is set to enter a Phase I dose-escalation therapeutic trial in multiple solid tumors with first patient dosing expected in the first quarter of 2026, in what is described as the first global clinical trial targeting B7H3 with a systemic radiopharmaceutical; alongside Betabart, two additional preclinical assets within Radiopharm Ventures have shown early positive data and are advancing toward final candidate selection in 2026, potentially strengthening Radiopharm’s position in the competitive cancer radiopharmaceuticals market and offering new avenues for growth for shareholders and partners.

The most recent analyst rating on (RADX) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited Sponsored ADR stock, see the RADX Stock Forecast page.